Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.

ABSTRACT:

Background

There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly.

Methods

In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models.

Results

Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years.

SUBMITTER: Hajiev S 

PROVIDER: S-EPMC7852559 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature